About the Company
Laura Elizabeth Niklason is a physician, professor and internationally recognized researcher in vascular and lung tissue engineering. She is the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale University and co-founder, chief executive officer and president of Humacyte, a regenerative medicine company developing bioengineered human tissues. Her work on lab-grown lungs was recognized as one of the top 50 most important inventions of 2010 by Time magazine. Niklason was included on Fortune’s “Digital Health Care Leaders” list in 2017 for her work in regenerative medicine. Niklason was inducted into the National Academy of Inventors in 2014. In 2015, she was elected to the National Academy of Medicine. In 2020, Niklason was elected a member of the National Academy of Engineering for cardiovascular tissue engineering, lung regeneration, and biomedical imaging. She holds more than 30 issued or pending patents in the United States.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Humacyte, Inc.
Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 11, 2025 Humacyte, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, ...
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) closed the most recent trading day at $2.40, moving -1.23% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.37% for the day.
Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ...
Despite a net loss, Humacyte Inc (HUMA) sees promising sales growth and strategic advancements in its Symvess product line.
Humacyte, Inc. to Release First Quarter 2025 Financial Results ... - Nasdaq
Humacyte, Inc. will announce its financial results for the first quarter of 2025 on May 13, 2025, during a conference call at 8:30 a.m. ET, where management will provide updates on corporate and ...
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc ...
News PR Newswire Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA ...
Humacyte, Inc. Announces Pricing of Public Offering of Common Sto
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Similar Companies
Loading the latest forecasts...